2004•Leukemia ResearchRequires access

Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): a trial of the Eastern Cooperative Oncology Group

William R. Friedenberg, Martin S. Tallman, Isadore Brodsky, Elisabeth M. Paietta, Jacob M. Rowe, Sandra J. Lee, Kendrith M. Rowland, George W. Schnetzer, John C. Reed

Open publisher page 10 citations

Abstract

This record does not include an abstract. Use the full-text link above if available.

About this research paper

What this paper is about

An abstract is not available in the OpenAlex record for this paper.

Why it matters

OpenAlex reports 10 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Key concepts: Medicine, Dexamethasone, Vincristine, Internal medicine, Chronic lymphocytic leukemia, Multiple drug resistance, Oncology, Complete response

Back to paper search Browse research topics Original source

Modified VAD and PSC-833 in the treatment of resistant or relapsing chronic lymphocytic leukemia (E4996): a trial of the Eastern Cooperative Oncology Group — Research Paper | ScholarLens